OPTI.GB OptiBiotix Health plc

TIDMOPTI

RNS Number : 9002Q

OptiBiotix Health PLC

01 July 2022

OptiBiotix Health plc

("OptiBiotix", the "Group" or the "Company")

Director Appointment and Director Dealing

OptiBiotix Health p lc (AI M: OPTI), a life sciences busi ness d eveloping compou n ds to tackle obesity, high cholesterol, diabetes and skin care, a nnounces the appointment of René Kamminga as a Director of the Company, with immediate effect and issue of options as part of his appointment. René is currently a Director and Chief Executive Officer of OptiBiotix Ltd, the Company's wholly owned prebiotic business.

Director appointment

René has more than 25 years' experience in the sale of speciality ingredients and products and joined OptiBiotix Ltd in March 2021 (RNS: 23 March 2021) from the position of Vice President of Business Development and Chief Commercial Officer of the Nutraceuticals division of one of the world's largest Omega-3 and fish oil refiners KD Pharma Group. As Chief Commercial Officer, René was integral in developing and delivering on a strategy of moving the business from bulk ingredients to finished product solutions. Prior to joining KD Pharma, René was President of Kerry Groups Texturants division with full P&L responsibility for its speciality ingredient business in Europe. Prior to this he worked in business director roles for Quest and Uniqema, subsidiaries of Unilever and ICI.

Since his appointment to OpiBiotix Ltd, René has brought experience of developing a business from selling bulk ingredients to finished product and a wealth of industry contacts in both the pharmaceutical and nutraceutical industries. He has a strong track record of rapidly growing sales and has been involved in a number of acquisitions in support of accelerating business growth. His experience of speciality food ingredients and high value final product solutions will help drive the business expansion of OptiBiotix' growing pipeline of microbiome modulation products and technologies.

René's appointment is part of a long-planned strategy to appoint experienced industry business leaders to lead each part of the business allowing the Group CEO to focus on identifying and developing new technologies and acquisition opportunities. His appointment to the main Board is recognition of the progress he has made in building OptiBiotix's prebiotic business.

Pursuant to Rule 17 and Schedule 2(g) of the AIM Rules for Companies, the following information is disclosed in respect of René Kamminga (aged 55):

 
 Current Directorships   Directorships in the past 
                          five years 
 OptiBiotix Limited      Kamminga Ventures BV 
                        -------------------------- 
 Alsoka BV 
                        -------------------------- 
 Kamminga Beheer BV 
                        -------------------------- 
 Care by Nature BV 
                        -------------------------- 
 

René Kamminga currently holds 55,844 shares in the Company, representing 0.06 per cent. of the Company's current issued share capital and options over 500,000 ordinary shares in the Company as part of the issue of options detailed below.

There is no further information regarding René required to be disclosed under the AIM Rules.

Director dealing and issue of options

As part of the OptiBiotix Share Option Plan, options over 500,000 new ordinary shares have been granted to René Kamminga (the "Options"). The Options are exercisable within 10 years at an exercise price of 2p per share, which will be subject to a combination of performance and time-based vesting criteria.

Stephen O'Hara, CEO of OptiBiotix, commented: "We are pleased to welcome René onto the Company's main Board in recognition of progress he has made in building OptiBiotix's prebiotic business as CEO of OptiBiotix Ltd. René's experience and track record of growing sales and network of industry contacts within the ingredients and nutraceutical industries will bring sector specific expertise to the Board and support continued growth in this exciting area of healthcare."

This announcement contains inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.

For further information, please contact:

 
 OptiBiotix Health plc                             www.optibiotix.com 
 Stephen O'Hara, Chief Executive                 Contact via Walbrook 
                                                                below 
 
 
 Cairn Financial Advisers LLP (NOMAD)              Tel: 020 7213 0880 
 Liam Murray / Jo Turner / Ludovico Lazzaretti 
 
 Cenkos Securities plc (Broker)                    Tel: 020 7397 8900 
 Callum Davidson / Neil McDonald 
 Michael Johnson / Russell Kerr (Sales) 
 
 Walbrook PR Ltd                                   Mob: 07876 741 001 
 Anna Dunphy 
 
 

Certain statements in this announcement, are, or may be deemed to be, forward looking statements. Forward looking statements are identi ed by their use of terms and phrases such as "believe", "could", "should" "envisage", "estimate", "intend", "may", "plan", "potentially", "expect", "will" or the negative of those, variations or comparable expressions, including references to assumptions. These forward looking statements are not based on historical facts but rather on the Directors' current expectations and assumptions regarding the Company's future growth, results of operations, performance, future capital and other expenditures (including the amount, nature and sources of funding thereof), competitive advantages, business prospects and opportunities. Such forward looking statements re ect the Directors' current beliefs and assumptions and are based on information currently available to the Directors.]

 
 Notification of a Transaction pursuant to Article 19(1) of Regulation 
  (EU) No. 596/2014 
 1      Details of the person discharging managerial responsibilities/person 
         closely associated 
       ---------------------------------------------------------------------------------------------- 
 a.     Name                                      René Kamminga 
       ----------------------------------------  ---------------------------------------------------- 
 2      Reason for notification 
       ----------------------------------------  ---------------------------------------------------- 
 a.     Position/Status                           Director 
       ----------------------------------------  ---------------------------------------------------- 
 b.     Initial notification/                     Initial Notification 
         Amendment 
       ----------------------------------------  ---------------------------------------------------- 
 3      Details of the issuer, emission allowance market participant, 
         auction platform, auctioneer or auction monitor 
       ---------------------------------------------------------------------------------------------- 
 a.     Name                                      OptiBiotix Health Plc 
       ----------------------------------------  ---------------------------------------------------- 
 b.     LEI                                       213800UKYQFT941QHS14 
       ----------------------------------------  ---------------------------------------------------- 
 4      Details of the transaction(s): section to be repeated for 
         (i) each type of instrument; (ii) each type of transaction; 
         (iii) each date; and (iv) each place where transactions have 
         been conducted 
       ---------------------------------------------------------------------------------------------- 
 a.     Description of                            Options over ordinary shares of 2p each 
         the financial 
         instrument, type 
         of instrument 
                                                   ISIN: GB00BP0RTP38 
         Identification 
         Code 
       ----------------------------------------  ---------------------------------------------------- 
 b.     Nature of the                             Issue of options over 500,000 ordinary shares 
         transaction                               as part of the Company Share Options Plan 
       ----------------------------------------  ---------------------------------------------------- 
 
 c.     Price(s) and volume(s)                     Price(s) per                  Volume(s) 
                                                    share 
       ----------------------------------------   ---------------------------- 
                                                   2p                            500,000 
                                                  ----------------------------  ------------------ 
 
 d.          Aggregated information 
               *    Volume                          N/A 
 
 
               *    Price 
       ----------------------------------------  ---------------------------------------------------- 
 e.     Date of the transaction                   1 July 2022 
       ----------------------------------------  ---------------------------------------------------- 
 f.     Place of the transaction                  London Stock Exchange, AIM 
       ----------------------------------------  ---------------------------------------------------- 
 

, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHWPUACQUPPGAU

(END) Dow Jones Newswires

July 01, 2022 02:00 ET (06:00 GMT)